83908-06-9

Basic information

• Product Name: Benzoic acid, 4-(bromomethyl)-2-hydroxy-, methyl ester
• CAS NO: 83908-06-9
• Molecular Formula: C9H9BrO3
• Molecular Weight: 245.073
• Mol File: 83908-06-9.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(bromomethyl)-2-hydroxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(bromomethyl)-2-hydroxy-, methyl ester(83908-06-9)
• EPA Substance Registry System: Benzoic acid, 4-(bromomethyl)-2-hydroxy-, methyl ester(83908-06-9)

Safety Data

• Hazardous Substances Data: 83908-06-9(Hazardous Substances Data)

Upstream product

• 4670-56-8 methyl 2-hydroxy-4-methylbenzoate 
• 50-85-1 2-hydroxy-p-toluic acid 

Downstream Products

• 1613293-06-3 N-((S)-1-(((R)-1-(7-((hexadecylamino)methyl)-4-oxo-4H-benzo-[d][1,3,2]dioxaborinin-2-yl)-3-methylbutyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide 
• 1613293-05-2 4-((hexadecylamino)methyl)-2-hydroxybenzoic acid 
• 311343-83-6 Methyl 2-Hydroxy-4-[({[3-hydroxy-4-(methoxycarbonyl)-phenyl]methyl}amino)methyl]benzoate Hydrochloride 
• 80235-10-5 2-hydroxy-4-(hydroxymethyl)benzoic acid methyl ester 
• 153953-53-8 C₂₁H₂₂N₂O₃⁽²⁺⁾ 

Relevant articles and documents

Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo

In this study, we describe the development of liposomal bortezomib nanoparticles, which was accomplished by synthesizing bortezomib prodrugs with reversible boronic ester bonds and then incorporating the resulting prodrugs into the nanoparticles via surface conjugation. Initially, several prodrug candidates were screened based upon boronic ester stability using isobutylboronic acid as a model boronic acid compound. The two most stable candidates were then selected to create surface conjugated bortezomib prodrugs on the liposomes. Our strategy yielded stable liposomal bortezomib nanoparticles with a narrow size range of 100 nm and with high reproducibility. These liposomal bortezomib nanoparticles demonstrated significant proteasome inhibition and cytotoxicity against multiple myeloma cell lines in vitro and remarkable tumor growth inhibition with reduced systemic toxicity compared to free bortezomib in vivo. Taken together, this study demonstrates the incorporation of bortezomib into liposomal nanoparticles via reversible boronic ester bond formation to enhance the therapeutic index for improved patient outcome.

TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxicity to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the invention also decrease the volume and weight of a tumor and have a strong angiogenesis inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the present invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.

Bifunctional boronic compound complexing reagents and complexes

Reagents suitable for the modification of a bioactive species for the purpose of incorporating a bifunctional boronic compound complexing moiety for subsequent conjugation to a different (or the same) bioactive species having pendant phenylboronic acid moieties of General Formula 1, wherein group R is an electrophilic or nucleophilic moiety suitable for reaction of the putative bifunctional boronic compound complexing reagent with a bioactive species, wherein group R2 is selected from one of H and OH moieties, and wherein group R3 is selected from one of an alkyl and a methylene bearing an electronegative substituent. Group Z is a spacer selected from (CH2)n and CH2O(CH2CH2O)n2, wherein n is an integer of from 1 to 5, and wherein n2 is an integer of from 1 to 4. Each of group Z2 and Z3 is a spacer selected from CH2Ar, CH2CONHCH2Ar, CH2CONH(CH2)n3CO-NHCH2Ar, and (CH2)n4NHCO(CH2)n5CONHCH2Ar, wherein the group Ar represents the aromatic ring in the reagent of General Formula I to which the spacer Z2 or Z3 is appended, wherein n3 is an integer of from 1 to 5, wherein n4 is an integer selected from one of 2 and 3, and wherein n5 is an integer of from 1 to 4. Reaction of a reagent of General Formula I with a bioactive species affords a conjugate having pendant putative bifunctional boronic compound complexing moieties. (one or more) The conjugate may be further reacted with hydroxylamine (NH2OH) by amidation of the benzoic acid ester moiety to afford a class of bifunctional boronic compound complexing conjugate, e.g., conjugate with one or more pendant bifunctional boronic compound complexing moieties.